Phase 3
N=93
Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
Stroke · Myocardial Infarctions
Bottom Line
View on ClinicalTrials.gov: NCT01586975 ↗Enrolled (actual)
93
Serious AEs
3.2%
Results posted
Dec 2015
Primary outcome: Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Clopidogrel (Drug); Aspirin 81 mg (Drug); Aspirin >300 mg (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwestern University
- Primary completion
- Apr 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY PFA1 |
202.0; 271.1; 234.7 | 0.0742 |
Summary
The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications. Hypothesis is antiplatelet agents will be more efficacious if they are administered in a dose-adjusted manner using PFA results as a guide.
Eligibility Criteria
Inclusion Criteria
- Patient must be taking Aspirin or Plavix
- Patient must have had a stroke, TIA or cerebrovascular disease
Exclusion Criteria
-None
Data sourced from ClinicalTrials.gov (NCT01586975). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.